Precision Oncology
Latin America · 2 shared keywords
Updated
Reviewed by Vidhi Upadhyay
Latin America Oncology Biosimilars Market Industry Trends and Forecast to 2034: Segmented by (Molecule, Cancer, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$1.64 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $498.0 Mn | — | — |
| 2025 (base) | $578.1 Mn | +$80.2 Mn | — |
| 2026 (forecast) | $671.2 Mn | +$93.1 Mn | +16.1% |
| 2027 (forecast) | $779.3 Mn | +$108.1 Mn | +34.8% |
| 2028 (forecast) | $904.7 Mn | +$125.5 Mn | +56.5% |
| 2029 (forecast) | $1.05 Bn | +$145.7 Mn | +81.7% |
| 2030 (forecast) | $1.22 Bn | +$169.1 Mn | +110.9% |
| 2031 (forecast) | $1.42 Bn | +$196.3 Mn | +144.9% |
| 2032 (forecast) | $1.64 Bn | +$228.0 Mn | +184.3% |
| 2033 (forecast) | $1.91 Bn | +$264.7 Mn | +230.1% |
| 2034 (forecast) | $2.22 Bn | +$307.3 Mn | +283.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $578.1 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $2.22 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 16.1% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Molecule, cancer and end user (see all) |
| Key players | Amgen Inc., Sandoz, Pfizer Inc., Celltrion, Samsung Bioepis and 1 more (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Oncology biosimilars are lower-cost versions of cancer biologic drugs such as trastuzumab and bevacizumab.
Key segments of the oncology Biosimilars market include molecule (Trastuzumab, Bevacizumab and Rituximab) and cancer (Breast, Colorectal and Lymphoma).
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the oncology Biosimilars market. Faster approvals and new combinations are improving survival.
Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the oncology Biosimilars market.
High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the oncology Biosimilars market, especially in low- and middle-income countries.
The oncology Biosimilars market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, medicines are approved by ANVISA (Brazil)[1], ARCSA (Ecuador)[2] and COFEPRIS (Mexico)[3]. How care is paid for in some of these countries: the SUS (Brazil)[4]; public care and IESS (Ecuador)[5]; and IMSS, ISSSTE and IMSS-Bienestar (Mexico)[6].
[1] ANVISA. Checked 14 Nov 2026.
[2] ARCSA. Checked 14 Nov 2026.
[3] COFEPRIS. Checked 14 Nov 2026.
[4] CONITEC. Checked 14 Nov 2026.
[5] Ministry of Public Health of Ecuador. Checked 14 Nov 2026.
[6] Mexican Social Security Institute (IMSS). Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for oncology Biosimilars. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Latin America.
What doctors and scientists are doing in Oncology Biosimilars right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Latin America · 2 shared keywords
Latin America · 2 shared keywords
Latin America · 1 shared keyword
Latin America · 1 shared keyword
Latin America · 1 shared keyword
Latin America · 1 shared keyword
Digital Health · Latin America
Medical Devices · Latin America
Healthcare Services · Latin America
Healthcare Services · Latin America
Healthcare Services · Latin America
Healthcare Services · Latin America